Literature DB >> 1499124

The use of the SoftPerm lens for the correction of irregular astigmatism.

E Maguen1, P Caroline, I R Rosner, J I Macy, A B Nesburn.   

Abstract

We evaluated the performance of the SoftPerm combined rigid gas permeable (RGP) and hydrogel lens for the visual correction of 49 eyes (30 patients) with irregular astigmatism. Follow-up was up to 15 months. An attempt was also made to compare the SoftPerm lens to its predecessor, the Saturn II lens. The most common etiology for irregular astigmatism was keratoconus. Others etiologies were penetrating keratoplasty and refractive surgery. Visual acuity improved significantly. Only two eyes were best corrected to 20/20 before fitting whereas, 13 eyes saw 20/20 after fitting. The rate of lens replacement was 0.22 lenses per eye per month. A variety of complications occurred, including corneal staining, abrasions, and edema. Complications also reflected the relative difficulty of handling of the lens, yet no vision threatening complications occurred. Overall, the SoftPerm lens is a vast improvement over the Saturn II and is a reasonable means of correction of irregular astigmatism.

Entities:  

Mesh:

Year:  1992        PMID: 1499124

Source DB:  PubMed          Journal:  CLAO J        ISSN: 0733-8902


  3 in total

1.  Rose K contact lens fitting for keratoconus.

Authors:  Yelda Buyru Ozkurt; Tomris Sengor; Sevda Kurna; Tufan Evciman; Semih Acikgoz; Melih Haboğlu; Suat Aki
Journal:  Int Ophthalmol       Date:  2007-10-23       Impact factor: 2.031

2.  A comparison of the visual acuity outcome between Clearkone and RGP lenses.

Authors:  Mohammadali Hassani; Ebrahim Jafarzadehpur; Ali Mirzajani; AbbasAli Yekta; Mehdi Khabazkhoob
Journal:  J Curr Ophthalmol       Date:  2017-08-26

3.  Fitting Tips and Visual Rehabilitation of Irregular Cornea with a New Design of Corneoscleral Contact Lens: Objective and Subjective Evaluation.

Authors:  Waleed Ali Abou Samra; Amani E Badawi; Hanem Kishk; Ayman Abd El Ghafar; Mohamed M Elwan; Hossam Youssef Abouelkheir
Journal:  J Ophthalmol       Date:  2018-02-01       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.